Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$26.60 USD

26.60
1,074,632

+0.05 (0.17%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $26.59 -0.01 (-0.02%) 5:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

How Alkermes (ALKS) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

by Zacks Equity Research

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.

Zacks Equity Research

Alkermes (ALKS) Q3 Earnings Match Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alkermes (ALKS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Alkermes (ALKS) closed the most recent trading day at $24.51, moving +0.62% from the previous trading session.

Zacks Equity Research

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

by Zacks Equity Research

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

Zacks Equity Research

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

by Zacks Equity Research

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

Zacks Equity Research

AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Zacks Equity Research

LHC Group (LHCG) to Expand Access in Georgia With New Buyout

by Zacks Equity Research

LHC Group (LHCG) is set to acquire Georgia-based Three Rivers Home Health that will expand its service footprint in 36 counties in the state of Georgia.

Zacks Equity Research

Merck (MRK) Enters Into Circular RNA Collaboration With Orna

by Zacks Equity Research

Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice

by Zacks Equity Research

The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.

Zacks Equity Research

Gilead (GILD) Announces Positive Data on Breast Cancer Drug

by Zacks Equity Research

Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.

Zacks Equity Research

Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint

by Zacks Equity Research

Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.

Zacks Equity Research

AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag

by Zacks Equity Research

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.

Zacks Equity Research

Are Medical Stocks Lagging Alkermes (ALKS) This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Elevance Health (ELV) have performed compared to their sector so far this year.

Zacks Equity Research

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

Zacks Equity Research

Here's Why You Should Buy Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Zacks Equity Research

Alkermes (ALKS) Could Find Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.

Zacks Equity Research

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well

by Zacks Equity Research

Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.

Zacks Equity Research

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

by Zacks Equity Research

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

Zacks Equity Research

CONMED (CNMD) Acquires Soft Tissue Implant Start-Up Biorez

by Zacks Equity Research

CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.

Zacks Equity Research

Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat

by Zacks Equity Research

Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.

Zacks Equity Research

Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data

by Zacks Equity Research

Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

Zacks Equity Research

Shockwave Medical (SWAV) Beats on Q2 Earnings & Revenues

by Zacks Equity Research

Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and expansion in gross margin.